-transparent.png){kind=logo}
Chlorambucil, a drug used in the treatment of neoplastic and non-neoplastic disease, was administered by gavage to BALB/c mice at a dose of 1.0 mg/kg body wt. 5 times per week for 12 weeks to test its carcinogenicity. The survival was statistically reduced in treated animals of both sexes (P less than 0.001). The treatment induced a significant increase in lung tumours (males, P less than 0.001; females, P less than 0.001) and lymphoreticular system tumours (males P less than 0.01; females, P less than 0.001) in both sexes and mammary carcinomas in female mice (P less than 0.05). These results with other investigations reported in literature, suggest that chlorambucil is carcinogenic in laboratory animals, mutagenic and that it could be a potential carcinogenic hazard to man.
A Cavaliere, and
N Pietropaoli, and
P F Alberti, and
R Vitali
April 1990,
Tumori,
A Cavaliere, and
N Pietropaoli, and
P F Alberti, and
R Vitali
October 1987,
Cancer letters,
A Cavaliere, and
N Pietropaoli, and
P F Alberti, and
R Vitali
October 1994,
Cancer letters,
A Cavaliere, and
N Pietropaoli, and
P F Alberti, and
R Vitali
January 1982,
Carcinogenesis,
A Cavaliere, and
N Pietropaoli, and
P F Alberti, and
R Vitali
July 1986,
Carcinogenesis,
A Cavaliere, and
N Pietropaoli, and
P F Alberti, and
R Vitali
December 1977,
Radiation research,
A Cavaliere, and
N Pietropaoli, and
P F Alberti, and
R Vitali
April 1982,
Journal of the National Cancer Institute,
A Cavaliere, and
N Pietropaoli, and
P F Alberti, and
R Vitali
April 2023,
Anticancer research,
A Cavaliere, and
N Pietropaoli, and
P F Alberti, and
R Vitali
November 1970,
Journal of the National Cancer Institute,
A Cavaliere, and
N Pietropaoli, and
P F Alberti, and
R Vitali
February 2006,
Molecular and cellular biochemistry,
